TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06766149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CogniFit Computerized Cognitive Training
Description: In the CogniFit Computerized Cognitive Training, children will complete a range of tasks covering a range of game-like exercises targeting various cognitive skills, including working memory, attention, and inhibitory control, with automatic level advancement after each exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cogmed Computerized Cognitive Training
Description: In the Cogmed Computerized Cognitive Training, children will complete a range of tasks covering a range of game-like exercises targeting various cognitive skills, including working memory and attentional control, with automatic level advancement after each exercise.
Study: NCT06775093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist
Description: 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: healthy lifestyle education
Description: 3 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: healthy lifestyle education
Description: 3 months
Study: NCT06770036

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation Resource Package for Caregivers
Description: The implementation resource package for caregivers is a set of resources provided to caregivers that aims to support their use of evidence-based behavior management practices and home-school communication strategies.
Study: NCT06775002

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Raman spectroscopy intelligent diagnostic system
Description: 1. Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures. 2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria. 3. The following is the general sequence of events during the 3 months evaluation period. 4. Completion of baseline procedures Participants were assessed for 3 months and completed all safety monitoring.
Study: NCT06774222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquinitinib: Take 4 mg QD for 2 weeks and stop for 1 week, every 3 weeks for a cycle; Standard chemotherapy: The selection of drugs is recommended by the 2024CSCO Guidelines for the Diagnosis and Treatment of Gastric Cancer, including SOX, XLOX or S-1, and the treatment cycle is one every 3 weeks
Study: NCT06775106

Intervention type: OTHER
Intervention: There is no intervention in this observational study
Description: No direct intervention will be done to patients eligible for the study. There will be a shunt placed to divert 5-15% of exhaled breath into a collection tube. This will not affect the patient's existing standard medical care.
Study: NCT06771375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing
Description: EMDR is a psychotherapeutic approach originally designed for individuals suffering from trauma and post-traumatic stress disorder (PTSD). It facilitates the processing of memories through a structured eight-phase treatment, involving the patient's focused attention on traumatic images, thoughts, and sensations while simultaneously engaging in bilateral stimulation, typically through guided eye movements. This process aims to reduce the emotional distress associated with aversive memories, promoting adaptive coping mechanisms and psychological healing. Recently, the indications for the method have been extended so that EMDR is also used for chronic pain and depressive disorders.
Study: NCT06770322

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional
Description: According to the clinician's own practice, the cuff of the endotracheal intubation tube will be manually inflated with the help of a syringe and the pressure will be measured with manometry and a note will be taken.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manometer
Description: The cuff pressure will be measured by manometry and the cuff of the endotracheal intubation tube will be inflated with 25-30 cmH2O.
Study: NCT06772428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nano-crystalline Megestrol Acetate Oral Suspension
Description: Nano-crystalline Megestrol Acetate Oral Suspension, with a specification of 125 mg/mL, the study group takes 5 mL orally per day (625 mg/day), and continues medication; after completing the treatment cycle, patients who are assessed by the researchers as suitable for continued treatment may continue to receive therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: radiotherapy ± chemotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: radiotherapy ± chemotherapy
Study: NCT06771362

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ART with Bulk-Fill composite
Description: Restoration using Bulk-fill flowable self-cured composite

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ART with Glass Ionomer
Description: Restoration Using High-Viscosity Glass Ionomer Cement
Study: NCT06770062

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Each subject will receive two cardiac MRI scans (with and without contrast), one preoperative and another 6-12 months after. The duration of each MRI is approximately 45-60 minutes
Study: NCT06771882

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BMOS technique
Description: The researcher obtained 5cc soaked in a 2cm×2 cm piece of sterilized gauze for every intervention administration.~* The preterm neonates were positioned in the supine position and the head turned to one side~* The gauze was placed near the head, 2cm away from the nose for 2 minutes before feeding to stimulate an olfactory sense of preterm neonates 3 times per day (11 am, 2 pm, and 5 pm).
Study: NCT06773650

Intervention type: OTHER
Intervention: Completion of online survey
Description: The online survey aims to reach a representative sample of the Italian population to identify their knowledge regarding LI
Study: NCT06771440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EPR search
Description: A stored query in the EPR, that checks for re-exposure to the culprit antibiotic or class-member, from the date of AAL registration to the date of patient inclusion
Study: NCT06771349

Intervention type: PROCEDURE
Intervention: sigmoidopexy
Description: Both Sigmoidectomy and sigmoidopexy can be used for the treatment of sigmoid volvulus. The former is the treatment of sigmoid volvulus by removing a portion of the sigmoid colon, and depending on the patient's condition, a bowel reconstruction or anastomosis may be performed to reattach the healthy bowel segment. The procedure may result in long-term bowel changes and may even require an stomy. sigmoidopexy is a procedure that immobilizes the sigmoid colon to the abdominal wall or pelvic structure, preventing it from twisting again.~The goal of sigmoidectomy is primarily to remove damaged or necrotic portions of the sigmoid colon and to treat complications resulting from sigmoid volvulus, especially when the volvulus results in intestinal necrosis, ischemia, or other serious complications. The goal of sigmoidopexy is to prevent the sigmoid from re-twisting by immobilizing the sigmoid, and it is suitable for those cases of sigmoid torsion without severe ischemia or necrosis.
Study: NCT06771661

Intervention type: OTHER
Intervention: Workshops
Description: The investigators will conduct workshops with parents to get closer to the main topic.

Intervention type: OTHER
Intervention: Focus group interviews
Description: The investigators will conduct focus group interviews with parents on their needs before and during child loss.

Intervention type: OTHER
Intervention: Narrative interviews
Description: The investigators will conduct narrative interviews with parents to gain an in-depth understanding of their lived experience before and during the intrauterine or perinatal child loss.

Intervention type: OTHER
Intervention: Delphi approach
Description: The investigators will carry out a Delphi approach with parents to translate and confirm or revise the findings into treatment recommendations for healthcare professionals.
Study: NCT04982848

Intervention type: DRUG
Intervention: Talzenna
Description: Talzenna treatment under Korea regulatory approval indication/dosage
Study: NCT05488197

Intervention type: OTHER
Intervention: uterine artery doppler at 18-23 weeks of pregnancy
Description: uterine artery doppler at 18-23 weeks of pregnancy

Intervention type: OTHER
Intervention: uterine artery doppler at 18-23 weeks of pregnancy
Description: uterine artery doppler at 18-23 weeks of pregnancy
Study: NCT05363878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Native HEALTH
Description: This application proposes the development and initial test of a culturally grounded, trauma informed intervention for alcohol use.
Study: NCT02393482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estroprogestinic therapy (Etinil-estradiol/levonorgestre)
Description: Etinil-estradiol/levonorgestrel (100 mcg/20 mcg)/die

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropin-releasing hormone agonist (Leuprorelin acetate)
Description: Leuprorelin acetate (3,75 mg/2 ml)/month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Add back therapy 1 (tibolone)
Description: tibolone 5 mg/die

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Add back therapy 2 (calcium carbonate/colecalciferol)
Description: calcium carbonate/colecalciferol (500mg/400UI)/die
Study: NCT05682118

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: roadmap
Description: FFR and iFR tests using the roadmap system, or FFR and iFR tests without using the roadmap system.~Pressure wire into guiding catheter The equalization of the pressure wire with the aortic pressure(after placing the pressure wire on the tip of the guiding catheter and removal of contrast media by saline flushing) and the placement of the pressure wire on the distal of the blood vessel to measure iFR. After iFR measurement, the pressure wire was pulled back into the tip of the guiding catheter to check the presence of pressure drift. A final Pd/Pa between 0.97 and 1.03 is considered acceptable. Following confirming no pressure drift, a mode change will be done from iFR to FFR, and then a re-check of the time between the equalization of the pressure wire with the aortic pressure will be planned. In all lesions, FFR value were measured with hyperemia, achieved by intracoronary (IC) bolus injection of nicorandil (Sigmart®; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) 2 mg.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iFR/FFR
Description: Patients undergoing pressure wire test with moderate stenosis. Pressure wire into guiding catheter The equalization of the pressure wire with the aortic pressure(after placing the pressure wire on the tip of the guiding catheter and removal of contrast media by saline flushing) and the placement of the pressure wire on the distal of the blood vessel to measure iFR. After iFR measurement, the pressure wire was pulled back into the tip of the guiding catheter to check the presence of pressure drift. A final Pd/Pa between 0.97 and 1.03 is considered acceptable. Following confirming no pressure drift, a mode change will be done from iFR to FFR, and then a re-check of the time between the equalization of the pressure wire with the aortic pressure will be planned. In all lesions, FFR value were measured with hyperemia, achieved by intracoronary (IC) bolus injection of nicorandil (Sigmart®; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) 2 mg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: iFR/FFR
Description: Patients undergoing pressure wire test with moderate stenosis. Pressure wire into guiding catheter The equalization of the pressure wire with the aortic pressure(after placing the pressure wire on the tip of the guiding catheter and removal of contrast media by saline flushing) and the placement of the pressure wire on the distal of the blood vessel to measure iFR. After iFR measurement, the pressure wire was pulled back into the tip of the guiding catheter to check the presence of pressure drift. A final Pd/Pa between 0.97 and 1.03 is considered acceptable. Following confirming no pressure drift, a mode change will be done from iFR to FFR, and then a re-check of the time between the equalization of the pressure wire with the aortic pressure will be planned. In all lesions, FFR value were measured with hyperemia, achieved by intracoronary (IC) bolus injection of nicorandil (Sigmart®; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) 2 mg.
Study: NCT06316921

Intervention type: PROCEDURE
Intervention: Epidural patient-controlled analgesia
Description: Epidural patient-controlled analgesia for postoperative pain after lumber spine surgery

Intervention type: PROCEDURE
Intervention: Standard postoperative pain management
Description: Standard of care for postoperative pain after lumber spine surgery
Study: NCT05991726

Intervention type: OTHER
Intervention: Other: Survey
Description: Multiple survey rounds identifying most important outcomes for effective self-management for non-dialysis CKD

Intervention type: OTHER
Intervention: Other: Survey
Description: Multiple survey rounds identifying most important outcomes for effective self-management for non-dialysis CKD
Study: NCT05689463

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: characterisation of immunoglobulin subclasses
Description: For patients with positive anti BP180 and/or anti BP230 serology, a characterisation of the immunoglobulin subclasses will be performed
Study: NCT05701670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Purrble+SSI
Description: Purrble intervention as described above.~Single Session Intervention (SSI) (\~30mins) combining the theories of ER with the experiences from students involved in previous studies, and follows a traditional SSI structure (Schleider et al 2020). Specific content has been co-produced with students and experts.
Study: NCT06080321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WhatsApp reminders
Description: Patients will receive active oral hygiene reminders in the form of WhatsApp messages one weekday each week. The standardized text message will be: This is a message from the Orthodontic Clinic at Faculty of Dentistry, Alexandria reminding you that it is extremely important to brush your teeth for 2 minutes after every meal or at least 3 times daily. Cleaning your teeth will help to keep them healthy and beautiful.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instagram reminders
Description: Patients will receive active oral hygiene reminders in the form of Instagram messages one weekday each week. The standardized text message will be: This is a message from the Orthodontic Clinic at Faculty of Dentistry, Alexandria reminding you that it is extremely important to brush your teeth for 2 minutes after every meal or at least 3 times daily. Cleaning your teeth will help to keep them healthy and beautiful.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone calls
Description: Patients will receive active oral hygiene reminders in the form of phone calls one weekday each week. The structured phone call will be: This is a message from the Orthodontic Clinic at Faculty of Dentistry, Alexandria reminding you that it is extremely important to brush your teeth for 2 minutes after every meal or at least 3 times daily. Cleaning your teeth will help to keep them healthy and beautiful.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Application alerts
Description: Patients will download an app on their mobile phones which has cleaning tips, demonstrations and alerts. The structured message will be: This is a message from the Orthodontic Clinic at Faculty of Dentistry, Alexandria reminding you that it is extremely important to brush your teeth for 2 minutes after every meal or at least 3 times daily. Cleaning your teeth will help to keep them healthy and beautiful.
Study: NCT06032793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Description: Pursed lip breathing, Diaphragmatic breathing and powered breathing
Study: NCT05407025

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood, urine, and tissue samples

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete risk factor questionnaire
Study: NCT05607420

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCART20x22
Description: Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptors given following a lymphodepletion regimen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLLS52
Description: A monoclonal antibody that recognizes a CD52 antigen
Study: NCT05955625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TIMELY
Description: The TIMELY app works with several devices, including a wearable activity tracker that collects activity levels, heart rate and sleep characteristics. Based on patient's activity levels, self-reported momentary mental states, health-related behaviours and environmental and clinical background factors, the app will enable patient-tailored recommendations relevant to improving lifestyle behaviours during daily life. In addition, patients will receive a blood pressure monitor that measures hemodynamic parameters through pulse wave analysis (PWA) and an easy-to-use ECG device which will be used to assess changes in heart rate and other cardiovascular measures at rest and with exercise.
Study: NCT06328010

Intervention type: BIOLOGICAL
Intervention: Advanced Treatment Modalities for wound and injuries
Description: Synthetic, Amniotic, Bovine, Porcine, or other non-human biological grafts or scaffolded grafts

Intervention type: BIOLOGICAL
Intervention: Standard of care
Description: Standard of care without use of grafts or scaffolded grafts

Intervention type: OTHER
Intervention: Retrospective wound treatment data collection
Description: Completed wound care treatment regardless of modality.
Study: NCT04280757

Intervention type: PROCEDURE
Intervention: Biopsied ICSI embryos (PGS)
Description: Biopsied ICSI embryos (PGS)
Study: NCT04771208

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: I kua na'u Let Me Carry Out Your Last Wishes
Description: A combination of Native Hawaiian advance care planning video decision support tool and personalized video declarations shared with providers and family members.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I kua na'u Let Me Carry Out Your Last Wishes
Description: A combination of Native Hawaiian advance care planning video decision support tool and personalized video declarations shared with providers and family members.
Study: NCT06641154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT-UGT1A1-AAV8-02
Description: Intravenous infusion, single dose
Study: NCT06644625

Intervention type: OTHER
Intervention: Blood draw for the laboratory assessment
Description: Screening blood sample collection to test for MGUS

Intervention type: OTHER
Intervention: Blood draw for the laboratory assessment
Description: Screening blood sample collection to test for MGUS
Study: NCT05820685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Participants in this arm will get acetaminophen 1000 mg every six hours, naproxen 500 mg every 12 hours, gabapentin 300 mg every eight hours, and Tramadol 50 mg every six hours as needed for breakthrough pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Participants in this arm will get acetaminophen 1000 mg every six hours, naproxen 500 mg every 12 hours, gabapentin 300 mg every eight hours, and Tramadol 50 mg every six hours as needed for breakthrough pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Participants in this arm will get Dronabinol 10 mg in addition to standard of care pain medication as needed for breakthrough pain
Study: NCT05602064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen is a non-steroidal anti-inflammatory drug which acts by reducing the production of cyclo-oxygenases (COX-1 and COX-2)- derived prostanoids in the blood

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Paracetamol is an analgesic that acts peripherally; although its primary site of action is still debatable, it is thought to inhibit prostaglandins in the hypothalamus

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo solution will be freshly prepared by an assistant in a manner to match the color and odor of the analgesics
Study: NCT05961930

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Surgeons will be asked to fill in a short questionnaire after surgery on risk of postoperative infection
Study: NCT04671888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: COPD patients will be asked to wear a data logger system to collect EMG data and respiration parameters during exercise that simulate daily activity (i.e., walking, cycling)
Study: NCT05890066

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-port laparoscopy
Description: Compare the effectiveness and safety between single-port and multi-port laparoscopic surgery
Study: NCT06451861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Induction Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Induction Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Induction Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azacitidine
Description: Induction Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Induction Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anthracyclines or anthraquinones
Description: Induction Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Description: Induction Therapy
Study: NCT05290194

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT radiotherapy + Conventionally fractionated radiotherapy
Description: Radiotherapy was performed 3-6 weeks after the end of first-line treatment, followed by conventional fractionated radiotherapy of the primary tumor and cervical lymph node metastases, SBRT radiotherapy of distant organ metastases 3-6 weeks later.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Immunotherapy of PD-1 inhibitor is used during the whole time of this trial until subjects were withdrawn from the trial or the trial complete

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is treated for patients 3-6 weeks after radiotherapy, which combines with PD-1 inhibitor as the maintenance regimen in the trial.